期刊
CANCER TREATMENT REVIEWS
卷 42, 期 -, 页码 41-46出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.10.011
关键词
Ovarian cancer; Platinum resistant; Recurrence; Gynecologic; Tyrosine-kinases inhibitors
类别
For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据